Related Experiment Video
Updated: Jun 5, 2026
10:36
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
Emerging gonadotropin-releasing hormone agonists
Daniel Alexander Beyer1, Feriel Amari, Marc Thill
1University of Schleswig Holstein, Department of Obstetrics and Gynaecology, Campus Lübeck, Ratzeburger Allee 160, D- 23538 Lübeck, Germany. daniel.beyer@uk-sh.de
Expert Opinion on Emerging Drugs
|January 20, 2011
Summary
Gonadotropin-releasing hormone agonist analogs (GnRHa) offer new therapeutic strategies for breast cancer and fertility preservation. Future developments aim for longer-acting GnRHa with enhanced antiproliferative effects.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Oncology
Background:
- Gonadotropin-releasing hormone agonist analogs (GnRHa) mimic GnRH to suppress sex steroid production.
- While established, GnRHa are subject to ongoing development and improvement.
Purpose of the Study:
- To discuss novel therapeutic strategies involving GnRH analogs.
- To provide a comprehensive understanding of GnRH agonists, their indications, and biochemical pathways.
Main Methods:
- Review of current and emerging applications of GnRH analogs.
- Discussion of recent findings from international meetings and debates on GnRH analog use.
- Exploration of GnRHa in breast cancer treatment, fertility preservation, and assisted reproduction.
Main Results:
- GnRHa are utilized in treating premenopausal breast cancer (estrogen-positive and -negative).
- GnRHa play a crucial role in fertility preservation for young female cancer patients.
- GnRH analogs are integral to assisted reproduction protocols.
Conclusions:
- There is a need for more complex and longer-acting GnRH analogs to improve patient adherence.
- Future oncological applications of GnRH analogs may extend beyond fertility preservation to harness their antiproliferative effects.
More Related Videos
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...